<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34169373</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1434-9949</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical rheumatology</Title>
          <ISOAbbreviation>Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Refractory fibromyalgia.</ArticleTitle>
        <Pagination>
          <StartPage>3853</StartPage>
          <EndPage>3858</EndPage>
          <MedlinePgn>3853-3858</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-021-05818-0</ELocationID>
        <Abstract>
          <AbstractText>In the medical literature, there are only a few references on refractory fibromyalgia and there is no consensus definition available on this concept. Some definitions of refractory fibromyalgia have been proposed based on the lack of response to a number of medications, and perhaps the most appropriate term is treatment-refractory fibromyalgia. To achieve the definition of treatment-refractory fibromyalgia, it is necessary to consider several previous steps, such as making sure the diagnosis has been made properly and a differential diagnosis with entities that can mimic fibromyalgia symptoms (including complete physical examination and laboratory test) has been made. The possibility that another factor that alters the response to treatment should be investigated, and in particular review all prescribed medication and search for some non-medical reasons that could mask the response to treatment (e.g., legal compensation). The definition of refractory fibromyalgia is complex and probably should include a lack of response to a specified number of drugs or to combination therapy with at least two non-pharmacological measures. In this article, it is not our purpose to present a formal definition, but to raise the possible bases for this purpose. We believe that it is a subject that must be discussed extensively before reaching a consensus definition. Key Points • There is no appropriate definition to classify fibromyalgia patients who do not respond to the usual pharmacological and non-pharmacological measures according to the national or international guidelines. • A consensus definition is required to classify these patients, which could help standardize future management strategies. In this article, we propose the bases on which refractory fibromyalgia could be defined.</AbstractText>
          <CopyrightInformation>© 2021. International League of Associations for Rheumatology (ILAR).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vidal</LastName>
            <ForeName>Luis F</ForeName>
            <Initials>LF</Initials>
            <AffiliationInfo>
              <Affiliation>Centro de Diagnóstico de Osteoporosis y Enfermedades Reumáticas (CEDOR), Lima, Perú.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Servicio de Reumatología, Hospital Nacional María Auxiliadora, Lima, Perú.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Messina</LastName>
            <ForeName>Osvaldo</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Investigaciones Reumatológicas y Osteológicas (IRO), Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Servicio de Reumatología, Hospital Argerich, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodríguez</LastName>
            <ForeName>Tamara</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Servicio de Reumatología, Hospital Clinic, Barcelona, España.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vidal</LastName>
            <ForeName>Maritza</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-8494-5260</Identifier>
            <AffiliationInfo>
              <Affiliation>Centro de Diagnóstico de Osteoporosis y Enfermedades Reumáticas (CEDOR), Lima, Perú. maritza.vidal55@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pineda</LastName>
            <ForeName>Carlos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>División de Enfermedades Musculoesqueléticas y Reumáticas, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, México City, México.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morales</LastName>
            <ForeName>Rasec</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Servicio de Reumatología, Hospital Nacional María Auxiliadora, Lima, Perú.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Collado</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Servicio de Reumatología, Hospital Clinic, Barcelona, España.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fibromyalgia Unit Coordinator, Hospital Clinic, Barcelona, España.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Clin Rheumatol</MedlineTA>
        <NlmUniqueID>8211469</NlmUniqueID>
        <ISSNLinking>0770-3198</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005356" MajorTopicYN="Y">Fibromyalgia</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Consensus definition</Keyword>
        <Keyword MajorTopicYN="N">Musculoskeletal pain</Keyword>
        <Keyword MajorTopicYN="N">Refractory fibromyalgia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>7</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34169373</ArticleId>
        <ArticleId IdType="doi">10.1007/s10067-021-05818-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s10067-021-05818-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Häuser W, Fitzcharles MA (2018) Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci 20(1):53</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31887/DCNS.2018.20.1/whauser</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold LM, Gebke KB, Choy EHS (2016) Fibromyalgia: management strategies for primary care providers. Int J Clin Pract 70(2):99–112</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ijcp.12757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heymann RE, Paiva ES, Martinez JE et al (2017) New guidelines for the diagnosis of fibromyalgia. Rev Bras Reumatol 57:s467-476</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rbr.2017.05.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ablin JN, Buskila D (2015) Update on the genetics of the fibromyalgia syndrome. Best Pract Res Clin Rheumatol 29(1):20–28</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.berh.2015.04.018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett R (2016) Shining a light on fibromyalgia treatment. Nat Rev Rheumatol 12(10):568–569</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2016.149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Copay AG, Subach R, Glassman SD et al (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541–546</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.spinee.2007.01.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choy EH, Arnold LM, Clauw DJ et al (2009) Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 36:2330–2334</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.090368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Revicki D, Hays RD, Cella D et al (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jclinepi.2007.03.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennet RM, Bushmakin AG, Cappelleri JC et al (2009) Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 36:1304–1311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.081090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geisser ME, Clauw DJ, Strand V et al (2010) Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 149:373–378</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.02.043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold LM, Zlateva G, Sadosky A et al (2011) Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 12:260–267</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1526-4637.2010.01047.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudson JI, Arnold LM, Bradley LA et al (2009) What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of four, randomized, placebo-controlled trials of duloxetine. J Rheumatol 36:2517–2522</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.090139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold LM, Williams DA, Hudson JI et al (2012) Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 64(3):885–894</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.33360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuesch E, Häuser W, Bernardy K et al (2013) Comparative efficacy of pharmacological and nonpharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2011-201249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holman A (1998) Effect of lorazepam on pain score for refractory fibromyalgia. Arthritis Rheum 41(9)</Citation>
        </Reference>
        <Reference>
          <Citation>Dworkin R, Sharma U, Stacey B et al (2005) Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. J Pain 6(3):S30</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpain.2005.01.116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stacey BR, Emir B, Petersel D et al (2010) Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J 4:35</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1874312901004010035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzcharles MA, Ste-Marie PA, Goldenberg DL et al (2013) Canadian guidelines for the diagnosis and management of Fibromyalgia syndrome: executive summary. Pain Res Manag 18(3):119–126</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/918216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzcharles MA, Shir Y, Ablin JN el at (2013) Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. Evid Based Complement Alternat Med 2013:485272</Citation>
        </Reference>
        <Reference>
          <Citation>Salaffi F, Gerardi MC, Atzeni F et al (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37(12):2035–2042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-017-3792-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzcharles MA, Perrot S, Häuser W (2018) Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain 22(9):1565–1576</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejp.1252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Häuser W, Perrot S, Sommer C et al (2017) Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep 2(3)</Citation>
        </Reference>
        <Reference>
          <Citation>López-Medina C, Moltó A (2020) Comorbid pain in axial spondyloarthritis, including fibromyalgia. Ther Adv Musculoskelet Dis 12:1759720X20966123</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1759720X20966123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arendt-Nielsen L, Nie H, Laursen MB et al (2010) Sensitization in patients with painful knee osteoarthritis. Pain 149(3):573–581</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.04.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fingleton C, Smart K, Moloney N et al (2015) Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil 23:1043–1056</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.joca.2015.02.163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazzichi L, Rossi A, Giuliano T et al (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115–2120</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-007-0636-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haliloglu S, Ekinci B, Uzkeser H et al (2017) Fibromyalgia in patients with thyroid autoimmunity: prevalence and relationship with disease activity. Clin Rheumatol 36(7):1617–1621</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-017-3556-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagoe CE, Sheth T, Golub E et al (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review. Clin Rheumatol 38(7):1801–1809</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-019-04498-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidal M, Lane NE (2020) The importance of vitamin D. Rheumatol Orthop Med 5. https://doi.org/10.15761/ROM.1000171</Citation>
        </Reference>
        <Reference>
          <Citation>Vidal LF, Morales R, Cueva C et al (2019) Serum levels of vitamin D in women treated at rheumatology services in Lima. Int J Clin Rheumatol 14(3):105–112</Citation>
        </Reference>
        <Reference>
          <Citation>Häuser W, Perrot S, Clauw DJ et al (2018) Unravelling fibromyalgia—steps toward individualized management. J Pain 19(2):125–134</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpain.2017.08.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Affaitati G, Costantini R, Fabrizio A et al (2011) Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 15(1):61–69</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpain.2010.09.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Häuser W, Ablin J, Perrot S et al (2017) Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med 127(1):47–56</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.20452/pamw.3877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith JD, Terpening CM, Schmidt SO et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35(6):702–706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1345/aph.10254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodd S, Horgan D, Malhi GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89(1–3):1–11</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jad.2005.08.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649–659</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(03)00231-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67(16)</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
